Suppr超能文献

氧化还原失衡:老年患者冠状动脉慢性完全闭塞的潜在治疗靶点。

Unbalanced Oxidant-Antioxidant Status: A Potential Therapeutic Target for Coronary Chronic Total Occlusion in Very Old Patients.

作者信息

Li Xia, Hu Youdong, Zhang Fenglin, Chen Ying, Zhou Hualan, Guo Dianxuan, Zhao Qingna

机构信息

Department of Geriatrics, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, Jiangsu 223002, China.

出版信息

Oxid Med Cell Longev. 2016;2016:4910829. doi: 10.1155/2016/4910829. Epub 2016 Dec 1.

Abstract

Unbalanced oxidant and antioxidant status played an important role in myocardial infarction. The present study was a clinical trial combined preclinically with targeted agent against cardiovascular injuries and ischemia in vivo model. We tried to confirm the association of unbalanced oxidant and antioxidant status with coronary chronic total occlusion (CTO) in 399 very old patients (80~89 years) and investigated the potential therapeutic value of purified polysaccharide from endothelium corneum gigeriae galli (PECGGp). We analyzed levels of circulating superoxide dismutase 3 (SOD3), nitric oxide (NO), endothelial nitric oxide synthase (eNOS), and malondialdehyde (MDA) in very old patients with coronary CTO. Levels of SOD3, NO, eNOS, and MDA in the cardiac tissue were measured in myocardial infarction rats. Levels of SOD3, eNOS, and NO were lowered ( < 0.001) and levels of MDA were increased ( < 0.001). PECGGp treatment increased levels of SOD3, eNOS, and NO ( < 0.01) in cardiac tissue, while decreasing levels of MDA ( < 0.01). PECGGp may suppress unbalanced oxidant and antioxidant status in infarcted myocardium by inhibiting levels of MDA and elevating NO, eNOS, and SOD3 levels. PECGGp could be considered as a potential therapeutic agent for coronary CTO in very old patients.

摘要

氧化应激与抗氧化状态失衡在心肌梗死中起重要作用。本研究是一项临床试验,临床前结合针对心血管损伤和体内缺血的靶向药物及模型。我们试图在399例80至89岁的高龄患者中证实氧化应激与抗氧化状态失衡与冠状动脉慢性完全闭塞(CTO)的相关性,并研究鸡内金内皮纯化多糖(PECGGp)的潜在治疗价值。我们分析了冠状动脉CTO高龄患者循环中超氧化物歧化酶3(SOD3)、一氧化氮(NO)、内皮型一氧化氮合酶(eNOS)和丙二醛(MDA)的水平。在心肌梗死大鼠中测量心脏组织中SOD3、NO、eNOS和MDA的水平。SOD3、NO、eNOS水平降低(<0.001),MDA水平升高(<0.001)。PECGGp治疗可提高心脏组织中SOD3、eNOS和NO的水平(<0.01),同时降低MDA水平(<0.01)。PECGGp可能通过抑制MDA水平、提高NO、eNOS和SOD3水平来抑制梗死心肌中氧化应激与抗氧化状态的失衡。PECGGp可被认为是高龄患者冠状动脉CTO的一种潜在治疗药物。

相似文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验